Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482758 | 0.73 | MGLL (0.45) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL9576348 | 0.68 | MGLL (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL3962885 | 0.65 | MGLL (0.44) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL31187422 | 0.65 | MGLL (0.44) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL3963636 | 0.62 | MGLL (0.46) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL3679923 | 0.62 | MGLL (0.41) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL10795168 | 0.62 | MGLL (0.39) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL31187420 | 0.62 | MGLL (0.46) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL819470 | 0.61 | — | — | |
| SCHEMBL6364235 | 0.59 | MGLL (0.44) | MGLLGSK3AGSK3BGMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420764-B2 | Compound having silsesquioxane skeleton and its polymer | JNC CORPORATION (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8236917-B2 | Compound having silsesquioxane skeleton and its polymer | JNC CORPORATION (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20120178894-A1 | COMPOUND HAVING SILSESQUIOXANE SKELETON AND ITS POLYMER | INAGAKI JYUN-ICHI (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20100240855-A1 | Compound having silsesquioxane skeleton and its polymer | JNC CORPORATION (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7705105-B2 | A cyclic polymer of silsesquioxane skeleton with side chains formed byhydrosilation of an unsaturated end group containing an active polymerfunctional group; polyimidesiloxane copolymers; polyestersiloxane copolymers; high molecular weight; thin films; strength; heat resistance;waterproofing; | CHISSO PETROCHEMICAL CORPORATION (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070190344-A1 | Verification of translation | JNC CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20050009982-A1 | Compound having silsesquioxane skeleton and its polymer | CHISSO CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009982-A1 | Compound having silsesquioxane skeleton and its polymer | C1S, H1-4, H1-0 | MGLL 4700/4885GSK3A 2699/4885GSK3B 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.